A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial

Demoly, Pascal; Corren, Jonathan; Creticos, Peter S.; Blay, F. De; Gevaert, Philippe; Hellings, Peter; Kowal, Krzysztof; Gall, M. Le; Ненашева, Н М; Passalacqua, Giovanni; Pfaar, Oliver; Tortajada‐Girbés, Miguel; Vidal, Carmen; Worm, Margitta; Casale, Thomas B.

doi:10.1016/j.jaci.2020.07.036

Cited by 72 publications

(80 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were randomized into a placebo and a SLIT group receiving a tablet containing a mixture of Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df) extract for 1 year. Active treatment achieved a relative least squares mean difference of 16.9% improvement of the total combined score in the tablet versus placebo group [ 33 ▪▪ ]. The latter study reflects well the magnitude of effect of SLIT with tablets observed in earlier large AIT trials [ 34 ].…”

Section: Allergen Extract-based Allergen-specific Immunothementioning

confidence: 99%

Novel vaccines for allergen-specific immunotherapy

Akinfenwa

Rodríguez-Domínguez

Vrtala

et al. 2020

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review Allergen-specific immunotherapy (AIT) is a highly economic, effective and disease-modifying form of allergy treatment but requires accurate prescription and monitoring. New molecular approaches are currently under development to improve AIT by reducing treatment-related side effects, cumbersome protocols and patients’ compliance. We review the current advances regarding refined diagnosis for prescription and monitoring of AIT and the development of novel molecular vaccines for AIT. Finally, we discuss prophylactic application of AIT. Recent findings There is evidence that molecular allergy diagnosis not only assists in the prescription and monitoring of AIT but also allows a refined selection of patients to increase the likelihood of treatment success. New data regarding the effects of AIT treatment with traditional allergen extracts by alternative routes have become available. Experimental approaches for AIT, such as virus-like particles and cell-based treatments have been described. New results from clinical trials performed with recombinant hypoallergens and passive immunization with allergen-specific antibodies highlight the importance of allergen-specific IgG antibodies for the effect of AIT and indicate opportunities for preventive allergen-specific vaccination. Summary Molecular allergy diagnosis is useful for the prescription and monitoring of AIT and may improve the success of AIT. Results with molecular allergy vaccines and by passive immunization with allergen-specific IgG antibodies indicate the importance of allergen-specific IgG capable of blocking allergen recognition by IgE and IgE-mediated allergic inflammation as important mechanism for the success of AIT. New molecular vaccines may pave the road towards prophylactic allergen-specific vaccination.

show abstract

Section: Allergen Extract-based Allergen-specific Immunothementioning

confidence: 99%

Novel vaccines for allergen-specific immunotherapy

Akinfenwa

Rodríguez-Domínguez

Vrtala

et al. 2020

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

show abstract

“… 14 Recent clinical trials in AR have shown the benefit (vs. placebo) of a 12 standardized quality (SQ) HDM sublingual AIT (sublingual immunotherapy [SLIT]) tablet or a 300 index of reactivity (IR) HDM SLIT tablet on rhinitis exacerbations (defined as a high total combined score, or a high symptom score with at least 1 symptom that was hard to tolerate, interfered with activities of daily living and/or sleeping). 15 , 16 …”

Section: Discussionmentioning

confidence: 99%

Worsening of chronic house-dust-mite-induced respiratory allergies: An observational survey in three European countries

Demoly

Bos

Vidal

2021

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Background Although respiratory allergies to house dust mites (HDMs) can often be controlled with symptomatic medications, some patients do not achieve satisfactory disease control. Objective To assess fortnightly fluctuations (notably worsening and/or exacerbations) in disease parameters among patients taking only symptomatic medications for HDM allergy. Methods In a 13-month, observational, multicenter survey of adults with a self-reported history of poorly controlled, moderate-to-severe, physician-diagnosed HDM respiratory allergy in France, Italy, and Spain, fortnightly telephone interviews were used to gather information on medication use, symptoms, the disease burden, and medical consultations from late May 2012 to early July 2013. Results A total of 313 patients completed the study ( n = 114 in Italy, 92 in France, and 107 in Spain). Although most participants reported improvements in symptoms, a substantial minority (ranging from 12% to 44% per fortnightly telephone interview in 2012 and from 16% to 37% in 2013) complained of worsening. A few study participants did not improve at any time in the study: 4% overall, and 2%, 2%, and 7% in Italy, France and Spain, respectively. A change in the weather and/or contact with other allergens were the most frequent self-reported reasons for worsening, although the answer “I don't know” was also prominent. Conclusion In a 13-month survey of patients with HDM allergy in Italy, France, and Spain, the participants’ symptom status fluctuated significantly — illustrating the complexity of this condition. Although most participants reported improvements, the “never-improver” profile warrants further investigation. More prominence could be given to symptom control and a low exacerbation risk as treatment goals in allergic rhinitis.

show abstract

“…A very recent, large trial showed that the 300IR house dust mite (HDM) tablet allergen immunotherapy (TAIT) was effective and safe for patients with HDMdriven allergic rhinitis [1]. The outcomes of this randomized controlled trial seem to be exciting, as suggesting fruitful practical information.…”

Section: To the Editormentioning

confidence: 99%

Tablet allergen immunotherapy (TAIT) requires tight management

Ciprandi

2021

Allergo J Int

View full text Add to dashboard Cite

A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial

Cited by 72 publications

References 55 publications

Novel vaccines for allergen-specific immunotherapy

Novel vaccines for allergen-specific immunotherapy

Worsening of chronic house-dust-mite-induced respiratory allergies: An observational survey in three European countries

Tablet allergen immunotherapy (TAIT) requires tight management

Contact Info

Product

Resources

About